top of page
Heart transparent.png
Heart transparent.png


Kidney transparent.png


Educational Need

The epidemic of obesity, diabetes, and aging of the United States population, continue to increase the number of patients who face the complications of these ailments. Heart, kidney, liver, and many other organs are at the stake. Advancements in the medicine are trying the best to address this epidemic. Fortunately, last decade has seen a dramatic increase in the availability of interventions, improved diagnostic techniques, and non-classical methods to imply these interventions. A continuing education program is one of the ways to disseminate these advancements happening at rapid rate to practicing physicians, nurses, and other health care professionals.


Course Description

The main goal of CRMC is to bring professionals from different specialties together to explore the pathophysiological interactions between obesity, diabetes, heart, and kidney disease in-depth and discuss further the role of currently available treatments and newer therapeutics to address these complications associated with metabolic disorders.

Additionally, state-of-the-art diagnostic techniques, therapeutic interventions and latest digital tools are discussed to help manage our complex patients suffering from cardiorenometabolic disorders.

Conference Objectives

1.   Understand the pathophysiological interactions between metabolic, cardiac and renal disorders.

2.   Learn the latest diagnostic techniques, and therapeutic intervention to manage obesity, cardiac and renal disorders.

3.   Implementation of interprofessional multidisciplinary approach to manage these complex disorders.

Who Should Attend

This activity is designed to meet the educational needs of physicians and other healthcare professionals who specialize in cardiology, nephrology, and metabolic disease.

Continuing Education Credit:

Continuing Medical Education (CME)

The UT Health Science Center San Antonio is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The UT Health Science Center at San Antonio designates this live activity for AMA PRA Category 1 Credit™. 


Nursing Continuing Professional Development Statement

CEs for nurses will be available.

Commission on Dietetic Registration (CDR) 

The Long School of Medicine is a Continuing Professional Education (CPE) Accredited provider with the Commission on Dietetic Registration (CDR). 


Texas Medical Board – Ethics Statement

Under review by the Texas Medical Board criteria for formal continuing medical education involving the study of medical ethics and/or professional responsibility.


Anand Prasad, MD, FACC, FSCAI, RPVI

A. Prasad.jpg

T. 123-456-7890

Anand Prasad, MD, FACC, FSCAI, RPVI
  • White LinkedIn Icon
  • White Google+ Icon
  • White Twitter Icon

Dr. Prasad graduated from Louisiana State University School of Medicine in New Orleans in 2000. He completed Internal Medicine and Cardiology training at the University of Texas Southwestern at Dallas. Subsequently, he completed an Interventional Cardiology and an Endovascular Fellowship at the University of California San Diego. He then joined the faculty at UC San Diego and after three years moved back to Texas to join the faculty at UT Health Science Center at San Antonio. He is a Professor of Medicine and holds the Freeman Heart Association Endowment in Cardiovascular Disease. He also is the Director of the UT/UHS Heart and Vascular Institute Catheterization Laboratories at University Health System. His clinical interests are centered on the endovascular treatment of peripheral arterial disease including carotid and lower extremity disease, transcatheter aortic valve replacement, percutaneous ventricular support devices and complex high risk percutaneous coronary interventions. Dr. Prasad has a focus on Vascular Medicine, is also board certified by the American Board of Vascular Medicine, and holds a certification as a Registered Physician in Vascular Interpretation (RPVI).

He has served as the Associate Program Director and Program Director for the Cardiovascular Diseases Fellowship Program at UT Health San Antonio. He is the Director of the Interventional Cardiology Fellowship Program. In addition to an active role in Fellow training, Dr. Prasad is involved with clinical research. He is the PI on both investigator-initiated and industry-sponsored clinical trials. His areas of current interest include novel approaches to therapy for limb salvage and acute kidney injury following endovascular interventions. He is also involved with efforts to understand subclinical vascular disease in minority populations and serves as a co-investigator in the Cameron County Hispanic Cohort Study. The goals of this endeavor are to understand the prevalence, predictors, and outcomes related to subclinical peripheral arterial disease in Mexican Americans. His research career has led to over 120 publications in peer-reviewed journals. He has served as the Associate Editor of Catheterization and Cardiovascular Interventions (CCI), Associate Peripheral Arterial Disease Section Editor for, on the ACC Interventional Section writing committee, ACC NCDR PVI Steering committee, XLPAD steering committee and on the editorial board for the Journal of Invasive Cardiology, JSCAI and editorial consultant for the Journal of the American College of Cardiology. The intersection of his research and clinical interests has led to the creation of the largest cardio-renal symposium in the United States: Cardio-Renal Connections. As co-founder of this meeting, Dr. Prasad has worked to bring together clinicians, nurses, students, researchers, and industry to better address the challenges in management of patients with concomitant heart and kidney disease.

Shweta Bansal, MD, FASN

After obtaining medical degree from SMS Medical College, Jaipur and Residency in Internal Medicine from New Delhi, India, Dr. Bansal moved to the Unites States in 2001, where she went on to complete Internal Medicine Residency and Nephrology Fellowship from the University of Colorado, Denver. There she also obtained the certificate in Public Health Sciences. Dr. Bansal joined the Division of Nephrology at UT Health San Antonio in 2010 and currently is a clinical Professor of Medicine and Director of Home Dialysis Program. Dr. Bansal adores the pathophysiological role kidneys play in health and diseases, particularly hypertension and heart failure, and is passionate about teaching this role to the medical students, residents, fellows, and colleagues. She has been highly recognized for her outstanding teaching abilities and won several teaching awards.  Her passion for education and cardiorenal interest led to the foundation of Annual Cardiorenal Connections (CRC) CME meeting in 2016 with cardiologist, Dr. Anand Prasad. Under their leadership and vision, CRC has achieved national and international fame and is the perfect venue for providers from different disciplines to come together and discuss the challenges we face on routine basis which are not addressed in specialty-specific conferences. As one of the founders, Dr. Bansal hopes that attendees enjoy this conference as much as she enjoys organizing it.

Shweta Bansal, MD

For patient care, Dr. Bansal strongly believes that empowerment of patients through health education is the most important step to achieve the best outcomes. Her establishment of home dialysis program at the partnered University Hospital System is a great example of patient empowerment and she fervently promotes this underutilized modality to the patients and fellows locally and nationally via participation in Home Dialysis University. She also serves as the chairs of education committee for North American chapter of International Society of Peritoneal Dialysis and is the member of American Society of Nephrology Home Dialysis task force. 

As the Program Director of Nephrology Fellowship (2017-2021), with implementation of innovative cardiorenal track, multiple electives, and night-float system, she put the program on national map and made it extremely competitive to attract quality applicants. She serves her profession through ABIM-Nephrology item-writing force, KSAP and NephSAP review panel. Dr. Bansal’s clinical and research interests focus on the volume/sodium control in the management of hypertension, CKD, dialysis and cardiorenal patients. She has received extra-mural and institutional grants and is the site-PI for NHLBI sponsored SPIRRIT-HF, TRIDENT consortium, Precision Medicine initiatives with NIH and several clinical industry grants. She has over 70 peer reviewed publications and chapters in high-impact journals such as Annals of Internal Medicine and JASN. She leads the Hub Liaison Team for Institutional Clinical and Translational Sciences Award. She also serves as the chair of the Institutional Review Board, Associate Editor for Journal Clinical Nephrology and member of many editorial boards.

Overall, Dr. Bansal strongly believes in academic medicine and its each domain - patient care, education, and research. She is humbled and privileged to have the current job that allows her to have a meaningful impact on the lives of her patients through clinical care and research activities, and the lives of medical students, residents, and fellows through teaching.

Carolina Solis-Herrera, MD

Carolina Solis-Herrera.jpg
Carolina Solis-Herrera, MD

Dr. Carolina Solis-Herrera is the Chief of the Endocrinology Division, Associate Professor of Medicine, and Physician-Scientist at the University of Texas Health at San Antonio (UTHSA), where she serves as the Medical Director of the Diabetes and Endocrinology Clinics. She received her M.D. (2002) from Universidad Autonoma de Baja California and completed a residency in Internal Medicine (2007) and a fellowship in Endocrinology (2009) from Universidad Nacional Autonoma de Mexico. After which, she came to UTHSA to complete a post-doctoral research fellowship in Diabetes and Metabolism Research, under Dr. Ralph Defronzo (2013), prior to retraining in Internal Medicine (2015) and Endocrinology (2017) at UTHSA. She Joined UTHSA as an Assistant Professor in 2017 and was promoted to Associate Professor in 2022. Administratively, Dr. Solis-Herrera has served as the Medical Director of the Diabetes and Endocrinology Clinics since 2019, one of the highest-ranked UT Physicians clinics for patient satisfaction in the region and was appointed Chief of the Division of Endocrinology in 2021, and Co-Director of the Center for Metabolic Health in 2023, where she is working on expanding and supporting treatment, discovery, and innovation against metabolic diseases, such as diabetes, prediabetes, obesity and fatty liver.

Dr. Solis-Herrera has received multiple awards, such as the 2024 UTHSA Presidential Clinical Excellence Award, was one of “Top Doctors in America 2023”, Bexar County Medical Society’s 2023 Extraordinary Women in Medicine, in 2022 was given a Hispanic Awareness Month Proclamation Award for Contributions to Advancement in Science and Health as part of City of San Antonio’s Mayor Ron Niremberg, 2022 Outstanding women in medicine, “San Antonio’s Best Female Doctor 2021” (published by the San Antonio Magazine), 2021 UT System Rising Star Award in Clinical Research, 2021 UTHSA Women in Medicine Honoree, “San Antonio Best Doctors 2020”, nomination to “Marquis Who is Who in America 2020”, is a Voelcker Scholar, and in 2021 was the recipient of the prestigious Doris Duke Charitable Foundation Clinical Scientist Development Award. She has obtained substantial intramural and extramural research funding and leads various trailblazing investigator initiated and industry-sponsored clinical trials.

Dr. Solis-Herrera is an Associate Editor for the Diabetes Spectrum Journal and serves as a National Grant Review Committee Member for JDRF and NIH. She has published >70 peer-reviewed publications and abstracts in highly esteemed journals in pursuit of her passion for Translational and Clinical Research in Diabetes and Metabolism. Her areas of research interests include mechanisms of action of novel anti-diabetic drugs, Cardio-metabolic Endocrinology, Obesity, and its complications, including Fatty Liver and MASH. Most recently, her group has focused on elucidating additional mechanisms of action of SGLT2 inhibitors, including endogenous glucose productions at the level of the kidney and mechanisms of cardiovascular protection.

Beyond her research and administrative duties, Dr. Solis-Herrera is strongly committed to medical education, teaching, and community outreach. Her ultimate goal, one she has been inexorably working on for the last 17 years, is to discover novel therapies to treat diabetes and obesity to improve outcomes and decrease complications for the millions who are affected by these conditions, and help in the training and development of the next generation of physician and scientists.

Course Desripion
Course Directors

The interplay between the kidneys, cardiovascular system, and metabolic disease is complex. The close relationship of renal function, cardiac function, and metabolic disease has given rise to the concept of cardio-renal-metabolic syndromes. This interplay extends beyond these syndromes and manifests itself in the form of hypertension, metabolic syndrome, and peripheral vascular disease. With the epidemic of diabetes and aging of the United States population, physicians will continue to face a growing number of patients with renal and cardiovascular disease. This CME program will serve to help foster education and discussion about the intersection of these three pathophysiologic systems.




  1. ​Robert W. Schrier, Shweta Bansal. Pulmonary hypertension, right ventricular failure, and kidney: different from left ventricular failure? Clin J Am Soc Nephrol 2008; 3(5): 1232-1237

  2. Robert W. Schrier, Shweta Bansal. Diagnosis and management of hyponatremia in acute illness. Curr Opin Crit Care 2008 Dec;14(6):627-34

  3. Shweta Bansal, JoAnn Lindenfeld, Robert W. Schrier. Sodium retention in heart failure and cirrhosis: Potential role of natriuretic doses of mineralocorticoid antagonist? Circ Heart Fail. 2009 Jul ;2(4):370-376

  4. Shweta Bansal, David Badesch, Todd Bull and Robert W. Schrier. Role of vasopressin and aldosterone in pulmonary arterial hypertension: A pilot study. Contemp Clin Trials 2009 Sep; 30(5): 392-9. Epub 2009 Apr 16.

  5. Subrata Debnath, Farook Thameem, Tahira Alves, Jacqueline Nolan, Hania Al-Shahrouri, Shweta Bansal, Hanna E. Abboud, and Paolo Fanti. Diabetic Nephropathy Among Mexican Americans. Clinical Nephrology 2012; 77(4):332-44.

  6. Marvin Eng, Shweta Bansal*. Use of Natriuretic-doses of Spironolactone for Treatment of Loop Diuretic Resistant Acute Decompensated Heart Failure. Int J Cardiol. 2014 Jan 1;170(3):e68-9. doi: 10.1016/j.ijcard.2013.11.023. Epub 2013 Nov 12

  7. SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015 Nov 26;373(22):2103-16. doi: 10.1056/NEJMoa1511939. Epub 2015 Nov 9

  8. Levin D, Bansal S, Prasad A. The Role of Novel Cardiorenal Biomarkers in the Cardiac Catheterization Laboratory for the Detection of Acute Kidney Injury. Rev Cardiovasc Med. 2016;17(3-4):100-114. PMID: 28144017.

  9. Bansal S. New insight into in to an old therapy for the treatment of acute decompensated heart failure and associated renal dysfunction.SM Journal of Cardiology and Cardiovascular Diseases 2016; 2: 1006

  10. Shweta Bansal*, Anand Prasad, Stuart Linas. Right Heart Failure - Unrecognized Causes of Cardiorenal Syndrome. Perspective in Journal of American Society of Nephrology. July 2018; 29: 1795-1798.

  11. SONAR investigators, Hiddo J L Heerspink, Hans-Henrik Parving, Dennis L Andress, George Bakris, Ricardo Correa-Rotter, Fan-Fan Hou, Dalane W Kitzman, Donald Kohan, Hirofumi Makino, John J V McMurray, Joel Z Melnick, Michael G Miller, Pablo E Pergola, Vlado Perkovic, Sheldon Tobe, Tingting Yi, Melissa Wigderson, Dick de Zeeuw.  Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet, published Online April 15, 2019,

  12. Shweta Bansal, Kristina Munoz, Sonja Brune, Steve Bailey, Anand Prasad, and Chakradhar Velagapudi.  Recognizing and Treating Loop-Diuretic Resistant Acute Decompensated Heart Failure with High-dose Spironolactone. Annals of Internal Medicine. Online July 16, 2019

bottom of page